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Introduction
Over  the  past  decades  numerous  common  molecular 
mechanisms  underlying  the  development  of  human 
cancers  have  been  identified.  It  now  seems  that  each 
subtype of human cancer is driven by a specific assort­
ment of selected cancer mechanisms. Notably, in various 
cancers the same basic mechanisms act in different ways 
and to different degrees. A theme identified in one cancer 
often turns up as a reprise with variations in others.
For  instance,  overactivation  of  the  canonical  Wnt 
signaling pathway is crucial to the development of many 
cancers in the gastrointestinal tract. In colorectal cancers 
constitutive pathway activity is caused predominantly by 
inactivation of its negative regulator APC, whereas the 
typical alteration in gastric and hepatocellular cancers is 
mutational activation of the central signal transducer β­
catenin. In genitourinary cancers, Wnt pathway activa­
tion is more subtle. In cancers of the kidney, bladder or 
prostate, mutations in intracellular Wnt pathway compo­
nents are rare and instead, epigenetic silencing of SFRP, 
DKK and WIF1 genes encoding extracellular Wnt antago­
nists is prevalent (Figure 1a). Presumably, these changes 
enhance the effect of paracrine or autocrine Wnt growth 
factors but do not lead to a constitutively active state of 
the  pathway  [1].  Why  these  differences  exist  is  an 
intriguing question for cancer researchers and develop­
mental biologists.
In  the  past,  many  cancer  mechanisms  ­  such  as  the 
pivotal role of Wnt signaling in colorectal cancer ­ were 
discovered  by  elucidating  the  function  of  single  genes, 
often  in  the  course  of  studying  rare  inherited  cancer 
syndromes. Large­scale genomic techniques have opened 
up new ways to investigate cancer mechanisms, especially 
in  cancer  types  that  are  not  associated  with  inherited 
syndromes,  which  include  the  common  cancers  of  the 
prostate and the urinary bladder. Over the past decade, 
array  techniques  for  gene  expression  profiling  and 
detection  of  gene  copy  number  changes  have  been 
instrumental.  More  recently,  high­throughput  sequen­
cing  techniques  have  begun  to  contribute  important 
insights by allowing comprehensive mutation detection 
or identification of in vivo transcription factor binding 
sites following chromatin immunoprecipitation (ChIP).
Renal cancer: aberrant hypoxia regulation as a 
primary mechanism in carcinogenesis
Investigations of clear­cell renal cell carcinoma (ccRCC), 
the major histological subtype of renal carcinoma, have 
highlighted the importance of hypoxia in cancer generally. 
Recent large­scale sequencing studies on ccRCC identified 
mutations predominantly in genes involved in the cellular 
response to hypoxia, including several chromatin modi­
fy  ing  or  remodeling  proteins  [2,3].  The  most  common 
genetic alterations in ccRCC lead to inactivation of the 
VHL  tumor  suppressor  gene,  which  is  mutated  in  the 
germline of patients suffering from the hereditary von­
Hippel­Lindau (VHL) tumor syndrome. A major conse­
quence of VHL functional loss is permanent activation of 
the hypoxia­induced factors HIF2α or HIF1α [4]. These 
transcription factors direct changes in cellular metabo­
lism,  enhance  angiogenesis,  activate  autocrine  growth 
factor  circuits,  and  induce  proapoptotic  proteins  in 
response to low oxygen. HIF1α is also induced in many 
other  human  cancers,  allowing  growth  and  survival 
under hypoxic conditions and promoting angiogenesis, 
but VHL inactivation is uncommon.
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© 2011 BioMed Central LtdNevertheless,  there  are  significant  differences  in  the 
details of how hypoxic regulation is disturbed between 
ccRCC and other cancers (Figure 1b). The activation of 
hypoxia responses by loss of VHL function is essentially 
unique to ccRCC and represents an early initiating event 
in  cancer  development.  Completely  independent  of 
actual  oxygen  availability,  these  cancers  execute  a 
program for the cellular response to hypoxia ­ achieving a 
Figure 1. Basic cancer mechanisms and their variations in different cancer types. (a) Wnt signaling is constitutively activated in colorectal 
cancers by mutations in intracellular components (red). In renal, urothelial and prostatic carcinomas epigenetic downregulation of extracellular 
modulators (yellow) prevails. (b) HIF is constitutively activated by loss of hypoxia regulators in renal cancers (red). In other cancers, actual hypoxia 
or regulation by oncogenic signal transduction pathways (yellow) increase HIF expression or activity. (c) During progression of prostate cancer (and 
other cancer types), increased EZH2 activity enhances methylation at histone H3 lysine 27 (H3K27, red) and seems to precipitate DNA methylation 
at some target genes. An alternative mechanism leading to increased H3K27 methylation at some genes in renal cell carcinomas involves loss 
of histone demethylases, such as UTX (orange). (d) The two obvious histological subtypes of urothelial carcinoma are distinguished by different 
genetic alterations. Mutations and chromosomal changes predominating in papillary tumors (yellow) activate signal transduction pathways that 
ultimately drive cell cycle progression. In invasive carcinomas, mutations and chromosomal changes (red) inactivate proximate regulators of cell 
cycle progression and checkpoints. Positive influences are illustrated by arrows and negative influences by T-bars. Abbreviations: APC, adenomatous 
polyposis coli protein; CDKN, cyclin-dependent kinase inhibitor; Chr., chromosome; DKK, dickkopf homolog; DNMT1, DNA methyltransferase; E2F, 
transcription factor E2F; EGFR, epidermal growth factor receptor; EZH2, enhancer of zeste homolog 2; FGFR, fibroblast growth factor receptor; FH, 
fumarate hydratase; GSK, glycogen synthase kinase; HIF, hypoxia-inducible factor; H-RAS, Harvey rat sarcoma viral oncogene homolog; JMJD3, 
jumonji C domain-containing protein; LEF, lymphoid enhancer-binding factor; MAPK, mitogen activating protein kinase; mTOR, mammalian 
target of rapamycin; P14ARF, alternate reading frame product of the CDKN2A gene; p16INK4A, inhibitor of cyclin-dependent kinase 4; p21, cyclin-
dependent kinase inhibitor p21CIP1; PHD, plant homeodomain homolog; PI3K/AKT, phosphatidylinositol 3-kinase/protein kinase AKT; PI3KCA, 
phosphatidylinositol 3-kinase p110 subunit alpha; RAS, rat sarcoma viral oncogene homolog; RB1, retinoblastoma 1; SDH, succinate dehydrogenase; 
SFRP, secreted frizzled-related protein; TCF, T-cell-specific transcription factor; TP53, tumor suppressor p53; UTX, ubiquitously-transcribed TPR gene 
on the X chromosome; VHL, von-Hippel-Lindau tumor suppressor; WIF, Wnt-inhibitory factor-1.
TCF/LEF
(a)
CCND1, MYC,
FOS, JUN
Wnt WIF
SFRP
DKK
APC GSK3
β-Catenin
Axin
Growth factor
receptor
PI3K/AKT
mTOR Oncogene
O2
Succinate
PHD
HIFα
VHL
FH SDH
O2
(b)
H3K27 UTX
JMJD3
Me
Me
H3K27
EZH2 DNMT1
(c) (d) FGFR3, EGFR
H-RAS Pl3KCA
Pl3K/AKT RAS/MAPK
RB1 TP53
E2F
P21
CDKN2A
Cell
cycle
P14ARF
Chr.9
P16INK4A
Schulz and Ribarska Genome Medicine 2011, 3:20 
http://genomemedicine.com/content/3/3/20
Page 2 of 5state consequently termed ‘pseudohypoxia’ . Pseudo  hypoxia 
may  lead  to  cancer  development  when  the  autocrine 
growth factor circuits it induces are stabilized while the 
concomitantly induced proapoptotic genes are silenced.
Intriguingly, a number of rare hereditary cancer syn­
dromes caused by mutations in unlikely tumor suppres­
sors, such as fumarate hydratase and succinate dehydro­
genase,  show  a  similarly  remarkable  preference  for 
causing  tumors  in  the  kidney,  albeit  not  necessarily 
ccRCC  [4].  In  these  cancers,  interruption  of  the  tri­
carboxylic acid cycle results in elevated levels of fumarate 
or  succinate,  leading  to  inhibition  of  the  proline  and 
asparagine  hydroxylases  that  prevent  HIF  stabilization 
and activation. By comparison, in other cancers, adap­
tation to hypoxia takes place during tumor progression 
when HIF1α is activated as a downstream consequence 
of  oncogenic  pathways.  In  many  cases,  these  act  via 
mammalian target of rapamycin (mTOR), a regulator of 
mRNA  translation  and  cell  growth.  Drugs  targeting 
aberrant HIF activation have been introduced into the 
clinic and have indeed proven efficacious, most of all in 
the treatment of metastatic ccRCC. They may be particu­
larly successful in this cancer because it depends uniquely 
on  this  mechanism,  not  only  for  angiogenesis.  In 
addition, the particular HIF activated in ccRCC is often 
HIF2α, which has a different spectrum of target genes 
from  HIF1α  [4].  Thus,  constitutive  activation  of  the 
hypoxic response seems to be a crucial primary mecha­
nism in renal carcinogenesis. It is tempting to speculate 
that the mutations in chromatin modifying and remodel­
ing proteins recently identified in RCC [2,3] may serve to 
stabilize this aberrant state.
Prostate cancer: histone modifying enzymes as 
oncogenes
The histone methyltransferase EZH2 has emerged as a 
major driver of prostate cancer carcinogenesis. A recent 
genome­wide ChIP study revealed that it interacts with 
the androgen receptor and the ETS family transcription 
factor ERG to establish the aberrant differentiation state 
of prostate cancers [5]. EZH2 and ERG had both been 
identified  as  overexpressed  in  prostate  cancer  by  gene 
expression  microarrays.  This  technique  has  not  only 
helped to elucidate novel mechanisms of prostate cancer 
development  and  progression,  but  has  also  provided 
biomarkers,  such  as  the  peroxisomal  protein  AMACR, 
which is now widely used to resolve ambiguous histolo­
gical findings in prostate biopsies [6].
EZH2 is the catalytic subunit of the Polycomb complex 
PRC2  and  catalyzes  trimethylation  of  histone  H3  on 
Lys27  (HeK27).  This  histone  modification  is  typically 
asso  ciated with gene repression, as is the case for DNA 
hypermethylation  of  CpG­island  promoters.  Indeed, 
these two events were subsequently found to be related 
(Figure 1c). In normal tissues, a subset of genes is marked 
by  H3K27me3  and  bound  by  PRC2.  These  genes  are 
normally weakly expressed or silent, but remain poised 
for activation. During carcinogenesis, they become fully 
silenced by DNA hypermethylation, often losing EZH2 
occupancy  and  the  H3K27me3  modification  in  the 
process. At some silenced genes, EZH2 and H3K27me3 
may directly attract DNA methyltransferases, whereas at 
others, DNA hypermethylation occurs independently of 
Polycomb proteins. Conversely, some EZH2 target genes 
remain repressed in cancers without becoming (DNA­) 
hypermethylated [7].
Meanwhile,  overexpression  of  EZH2  and  other  poly­
comb proteins, especially BMI1, has been observed in a 
range of other common and rare cancers. The specific 
histone modification established by EZH2 is reversed by 
the histone demethylases UTX and JMJD3. Intriguingly, 
UTX is inactivated by mutations in renal carcinomas [2]. 
These  findings  reveal  a  novel  cancer  mechanism,  in 
which aberrant activity of epigenetic regulatory repressor 
proteins or inactivation of their antagonists drives cancer 
progression and facilitates DNA hypermethylation. They 
open a wealth of opportunities for diagnostic and thera­
peutic approaches in urological and other cancers.
Urothelial cancers: distinguishing two routes to 
cancer
Urothelial  carcinoma,  the  major  histological  type  of 
bladder  cancer  and  the  fifth  most  common  non­
cutaneous cancer in industrialized countries, manifests 
as  one  of  two  subtypes,  papillary  tumors  and  more 
aggressive invasive cancers. Invasive cancers arise either 
from a flat high­grade dysplasia, from carcinoma in situ, 
or  by  progression  from  papillary  tumors.  Papillary 
cancers  have  near­diploid  genomes,  whereas  invasive 
carcinomas  are  characterized  by  marked  chromosomal 
instability [8]. Recent studies integrating global analyses 
of  gene  expression  and  genetic  alterations  clarify  the 
different mechanisms acting in these subtypes [9].
Papillary  tumors  have  a  characteristic  set  of  genetic 
changes: mutations activating the fibroblast growth factor 
receptor FGFR3, signal­transducing RAS proteins (most 
often  HRAS)  or  the  catalytic  subunit  of  phosphatidyl­
inositol 3­kinase PIK3CA. In addition, loss of chromo­
some 9 is frequent, targeting CDKN2A at 9p21 (encoding 
the cell cycle regulator p16INK4A and the activator of p53 
p14ARF) and various genes on 9q, such as TSC1 (an inhibi­
tor of mTOR). Normal urothelial cells proliferate rapidly 
but transiently after tissue damage or in culture, under 
the influence of autocrine and paracrine factors of the 
epidermal growth factor (EGF) and FGF family, which in 
turn  act  through  the  mitogen  activated  protein  kinase 
and  phosphatidylinositol  3­kinase  signal  transduction 
pathways. The characteristic genetic changes in papillary 
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same pathways, leading to continuous growth.
Except for chromosome 9 loss, the typical mutations in 
papillary tumors are less common in invasive urothelial 
cancers,  which  are  instead  often  characterized  by 
inactivation of the p53 and retinoblastoma protein (RB1) 
cellular  control  systems  through  various  mechanisms 
(Figure 1d), alongside many other changes. Evidently, the 
inactivation  of  the  p53  and  RB1  systems  compromises 
the  function  of  cell  cycle  checkpoints  responding  to 
telomere erosion, chromosomal instability, and oncogene­
induced  irregular  replication.  In  addition,  checkpoint 
signaling through ATR and CHK protein kinases is also 
suppressed in these cancers. Together, these changes may 
account for the limited effect of cytotoxic chemotherapy 
in the treatment of invasive bladder cancers. They could 
also  be  very  pertinent  to  therapies  using  novel  drugs 
directed at signal transduction pathways. Loss of the p53 
and pRB1 control systems may uncouple proliferation of 
the  tumor  cells  from  extracellular  signals,  diminishing 
the  requirement  for  signaling  through  these  pathways. 
Tellingly,  signatures  of  the  overactive  transcription 
factors E2F1 or E2F3, which are normally restrained by 
RB1  from  driving  cell  proliferation  and  replication, 
dominate  the  expression  profiles  of  invasive  bladder 
cancers and distinguish them from papillary tumors [10].
The assortment of genetic changes observed in invasive 
urothelial carcinomas is similar to that encountered in 
other  carcinomas,  for  example  lung  cancers  and 
squamous cell carcinomas. With the expected variations, 
the  theme  emerging  from  the  comparison  of  papillary 
and invasive bladder cancers might therefore be relevant 
in the pathogenesis of these cancers as well. For instance, 
the  limited  efficacy  of  small­molecule  EGF  receptor 
inhibitors in lung cancers and metastatic colorectal carci­
nomas may be caused not only by downstream mutations 
in signal transduction pathways, but also by an analogous 
uncoupling of cell cycle progression and cell proliferation 
from pathways driven by growth factor receptors by p53 
mutations and RB1 inactivation.
Conclusions
Basic mechanisms driving cancer development frequently 
recur in different cancer types, but more often than not 
with  variations  that  have  ramifications  that  extend 
beyond  heuristics  to  the  design  of  novel  therapeutic 
approaches. Many new questions follow from the insights 
sketched above. For instance, which mechanisms cause 
the  constitutive  activation  of  the  hypoxic  response  in 
ccRCC  cases  lacking  VHL  mutations?  Are  these  more 
similar to those mediating adaptation to hypoxia in other 
cancer types? Which targets of the epigenetic repression 
elicited by EZH2 deregulation in prostate cancers (and 
others)  are  crucial  for  pathogenesis  and  accessible  to 
therapeutic approaches? How can urothelial (and other) 
cancers with overactive signal transduction pathways be 
reliably  distinguished  from  those  with  failure  of  the 
central p53 and RB1 control systems in clinical practice, 
and which molecular targets for therapy can be chosen in 
cancers  largely  independent  of  extracellular  signaling 
pathways? The techniques for genomic analyses that have 
been available in the past decade have helped to define 
these  questions  and  the  new  generation  of  techniques 
should help to answer them, hopefully soon.
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